Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Septembre 2023 - 10:01PM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company
dedicated to breaking through barriers in gene therapy and
neurology, has entered into employment agreements with three
newly-hired employees that, among other things, provide for the
grant to such employees of non-qualified stock options and
restricted stock units as inducements material to such employees’
entering into employment with Voyager. The inducement awards were
approved by the Compensation Committee of Voyager’s Board of
Directors in accordance with Nasdaq Stock Market Listing Rule
5635(c)(4). The option awards to two of these employees became
effective on September 5, 2023, and the option award to the third
employee became effective on September 6, 2023. The restricted
stock unit award to each employee is scheduled to become effective
on October 1, 2023.
The stock option award to two employees provides for the
purchase of an aggregate of 90,000 shares of Voyager’s common
stock, and the restricted stock unit award to such employees will
represent 45,000 shares of Voyager’s common stock. The stock option
award to the third employee provides for the purchase of an
aggregate of 44,000 shares of Voyager’s common stock, and the
restricted stock unit award to such employee will represent 22,000
shares of Voyager’s common stock. Each stock option has a ten-year
term. The stock option awards to the two employees have an exercise
price of $9.26 per share, which is equal to the closing price of
Voyager's common stock on September 5, 2023, the effective date of
grant. The stock option to the third employee has an exercise price
of $9.39 per share, which is equal to the closing price of
Voyager's common stock on September 6, 2023, the effective date of
grant. Each stock option vests over four years, with 25% of the
shares underlying the stock option vesting on the first anniversary
of the effective date of grant and 75% of the shares underlying the
stock option vesting in 36 equal monthly installments following the
first anniversary of the effective date of grant. Each restricted
stock unit award vests annually in equal installments over three
years, beginning on the first anniversary of the effective date of
grant. Vesting of each employee’s equity awards is subject to such
employee’s continued employment with Voyager. Each equity award is
also subject to the terms and conditions of an award agreement.
About Voyager Therapeutics Voyager
Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to
breaking through barriers in gene therapy and neurology. The
potential of both disciplines has been constrained by delivery
challenges; Voyager is leveraging cutting-edge expertise in capsid
discovery and deep neuropharmacology capabilities to address these
constraints. Voyager’s TRACER™ AAV capsid discovery platform has
generated novel capsids with high target delivery and blood-brain
barrier penetration at low doses, potentially addressing the narrow
therapeutic window associated with conventional gene therapy
delivery vectors. This platform is fueling alliances with Pfizer
Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo
Therapeutics, Inc., as well as multiple programs in Voyager’s own
pipeline. Voyager’s pipeline includes wholly owned and
collaborative preclinical programs in Alzheimer’s disease,
amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other
diseases of the central nervous system, with a focus on validated
targets and biomarkers to enable a path to rapid potential
proof-of-biology. For more information, visit
www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and
TRACER™ is a trademark, of Voyager Therapeutics, Inc.
InvestorsInvestors@vygr.com
MediaPeg
Rusconiprusconi@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Voyager Therapeutics (NASDAQ:VYGR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024